NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, Price Target & More

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) issued its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.24. The specialty pharmaceutical company had revenue of $0.91 million for the quarter, compared to analysts' expectations of $1.11 million. Foamix Pharmaceuticals had a negative return on equity of 103.64% and a negative net margin of 2,119.19%. View Foamix Pharmaceuticals' Earnings History.

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Foamix Pharmaceuticals.

2 brokerages have issued 12-month target prices for Foamix Pharmaceuticals' stock. Their predictions range from $8.00 to $12.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Ratings for Foamix Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Foamix Pharmaceuticals include Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG), True Drinks Holdings, Inc Common Stock (TRUU), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).

Media stories about FOMX stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.17 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 45.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Foamix Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.96%). Company insiders that own Foamix Pharmaceuticals stock include David Domzalski, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.

FOMX stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB. View Insider Buying and Selling for Foamix Pharmaceuticals.

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FOMX stock can currently be purchased for approximately $5.44.

Foamix Pharmaceuticals has a market capitalization of $219.94 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]